EPS for Sapiens International N.V. (SPNS) Expected At $0.11; Aldeyra Therapeutics (ALDX) Shorts Down By 6.05%

October 13, 2017 - By Winifred Garcia

Analysts expect Sapiens International Corporation N.V. (NASDAQ:SPNS) to report $0.11 EPS on November, 6.They anticipate $0.01 EPS change or 8.33% from last quarter’s $0.12 EPS. SPNS’s profit would be $5.39M giving it 31.18 P/E if the $0.11 EPS is correct. After having $0.03 EPS previously, Sapiens International Corporation N.V.’s analysts see 266.67% EPS growth. About 7,037 shares traded. Sapiens International Corporation N.V. (NASDAQ:SPNS) has risen 15.78% since October 13, 2016 and is uptrending. It has underperformed by 0.92% the S&P500.

Aldeyra Therapeutics Incorporated (NASDAQ:ALDX) had a decrease of 6.05% in short interest. ALDX’s SI was 118,100 shares in October as released by FINRA. Its down 6.05% from 125,700 shares previously. With 14,400 avg volume, 8 days are for Aldeyra Therapeutics Incorporated (NASDAQ:ALDX)’s short sellers to cover ALDX’s short positions. The SI to Aldeyra Therapeutics Incorporated’s float is 4.94%. About 198,229 shares traded. Aldeyra Therapeutics Inc (NASDAQ:ALDX) has declined 18.94% since October 13, 2016 and is downtrending. It has underperformed by 35.64% the S&P500.

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The company has market cap of $132.99 million. The Company’s principal activities include raising capital and research and development activities. It currently has negative earnings. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Among 4 analysts covering Aldeyra Therapeutics Inc (NASDAQ:ALDX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics Inc had 10 analyst reports since August 13, 2015 according to SRatingsIntel. The rating was initiated by Cowen & Co on Tuesday, September 8 with “Outperform”. The stock has “Buy” rating by H.C. Wainwright on Thursday, June 15. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, August 9 report. Stifel Nicolaus initiated the shares of ALDX in report on Friday, July 1 with “Buy” rating. The stock of Aldeyra Therapeutics Inc (NASDAQ:ALDX) earned “Buy” rating by Cowen & Co on Wednesday, August 9. Cowen & Co maintained the shares of ALDX in report on Thursday, September 14 with “Buy” rating. The firm has “Buy” rating by H.C. Wainwright given on Monday, September 26. As per Wednesday, June 14, the company rating was maintained by Canaccord Genuity. The stock of Aldeyra Therapeutics Inc (NASDAQ:ALDX) earned “Buy” rating by Canaccord Genuity on Wednesday, September 13.

Investors sentiment decreased to 1.67 in 2017 Q2. Its down 0.66, from 2.33 in 2017Q1. It turned negative, as 3 investors sold Aldeyra Therapeutics Inc shares while 6 reduced holdings. 7 funds opened positions while 8 raised stakes. 7.44 million shares or 2.21% less from 7.60 million shares in 2017Q1 were reported. Sei Investments owns 1,800 shares. Royal Comml Bank Of Canada reported 0% in Aldeyra Therapeutics Inc (NASDAQ:ALDX). State Bank Of America De holds 9,000 shares. 683 Capital Mgmt Ltd Limited Liability Company reported 0.36% stake. Weiss Multi accumulated 62,000 shares. Morgan Stanley accumulated 0% or 2,796 shares. Fmr Ltd Liability Corporation reported 1.65 million shares stake. New York-based Perceptive Advsr Lc has invested 0.68% in Aldeyra Therapeutics Inc (NASDAQ:ALDX). Northern Corporation holds 0% or 14,999 shares. Adage Capital Prtn Group Lc, Massachusetts-based fund reported 475,000 shares. Tower Research Limited Co (Trc) has 12 shares. New York-based Millennium Ltd Liability Co has invested 0% in Aldeyra Therapeutics Inc (NASDAQ:ALDX). Prelude Ltd has 0% invested in Aldeyra Therapeutics Inc (NASDAQ:ALDX) for 2,451 shares. Knoll Capital Management Lp reported 124,096 shares or 0.77% of all its holdings. Vanguard Group Incorporated Inc holds 0% in Aldeyra Therapeutics Inc (NASDAQ:ALDX) or 304,633 shares.

Sapiens International Corporation N.V. is a well-known provider of software solutions for the insurance industry, with a focus on the financial services sector. The company has market cap of $672.77 million. The Firm operates in well-known provider of software solutions segment. It has a 200.73 P/E ratio. The Company’s software solutions portfolio consists of Life, Pension, Annuity and Retirement Solutions, including software solutions for the management of a range of products for life, pension, annuity and retirement; Property and Casualty/General Insurance Solutions, including a software suite of solutions, supporting a range of business lines, including personal, commercial and specialty lines, as well as a solution for the management of reinsurance contracts; Sapiens DECISION, which is a business decision management solution, and Technology-Based Solutions, such as Sapiens eMerge.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com